Amends the Federal Food, Drug, and Cosmetic Act to require that priority review vouchers, which are given by the Secretary of Health and Human Services to the sponsor of a tropical disease product application, are transferable to sponsors of human drug applications for approval of a new drug or biological product. Prohibits such vouchers from being redeemed to affect the review of a pending human drug application.